Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Long-Term Debt Repayments (2016 - 2025)

Amphastar Pharmaceuticals has reported Long-Term Debt Repayments over the past 13 years, most recently at $104000.0 for Q4 2025.

  • Quarterly results put Long-Term Debt Repayments at $104000.0 for Q4 2025, down 9.57% from a year ago — trailing twelve months through Dec 2025 was $223000.0 (down 97.3% YoY), and the annual figure for FY2025 was $223000.0, down 97.3%.
  • Long-Term Debt Repayments for Q4 2025 was $104000.0 at Amphastar Pharmaceuticals, up from $44000.0 in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for AMPH hit a ceiling of $200.1 million in Q3 2023 and a floor of $37000.0 in Q2 2025.
  • Median Long-Term Debt Repayments over the past 5 years was $565500.0 (2022), compared with a mean of $18.3 million.
  • Biggest five-year swings in Long-Term Debt Repayments: soared 39081.25% in 2023 and later plummeted 99.98% in 2024.
  • Amphastar Pharmaceuticals' Long-Term Debt Repayments stood at $613000.0 in 2021, then tumbled by 79.12% to $128000.0 in 2022, then soared by 39081.25% to $50.2 million in 2023, then tumbled by 99.77% to $115000.0 in 2024, then fell by 9.57% to $104000.0 in 2025.
  • The last three reported values for Long-Term Debt Repayments were $104000.0 (Q4 2025), $44000.0 (Q3 2025), and $37000.0 (Q2 2025) per Business Quant data.